{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T22:43:21Z","timestamp":1743979401410},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,12]]},"DOI":"10.7759\/cureus.22159","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T01:50:20Z","timestamp":1644717020000},"source":"Crossref","is-referenced-by-count":2,"title":["Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab"],"prefix":"10.7759","author":[{"given":"Rebekah","family":"Rittberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepu","family":"Alex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00187","article-title":"Immunotherapy in malignant pleural mesothelioma","volume":"10","author":"de Gooijer CJ","year":"2020","unstructured":"de Gooijer CJ, Borm FJ, Scherpereel A, Baas P. Immunotherapy in malignant pleural mesothelioma. Front Oncol. 2020, 10:187. 10.3389\/fonc.2020.00187","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas P","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, et al.. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021, 397:375-386. 10.1016\/S0140-6736(20)32714-8","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.04.006","article-title":"The abscopal effect of stereotactic radiotherapy and immunotherapy: fool's gold or el dorado?","volume":"31","author":"Xing D","year":"2019","unstructured":"Xing D, Siva S, Hanna GG. The abscopal effect of stereotactic radiotherapy and immunotherapy: fool's gold or el dorado?. Clin Oncol (R Coll Radiol). 2019, 31:432-43. 10.1016\/j.clon.2019.04.006","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine?","volume":"26","author":"MO RH","year":"1953","unstructured":"MO RH. Whole body irradiation; radiobiology or medicine?. Br J Radiol. 1953, 26:234-41. 10.1259\/0007-1285-26-305-234","journal-title":"Br J Radiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2015.10.001","article-title":"Systematic review of case reports on the abscopal effect","volume":"40","author":"Abuodeh Y","year":"2016","unstructured":"Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016, 40:25-37. 10.1016\/j.currproblcancer.2015.10.001","journal-title":"Curr Probl Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4102","article-title":"First-ever abscopal effect after palliative radiotherapy and immuno-gene therapy for malignant pleural mesothelioma","volume":"11","author":"Barsky AR","year":"2019","unstructured":"Barsky AR, Cengel KA, Katz SI, Sterman DH, Simone CB 2nd. First-ever abscopal effect after palliative radiotherapy and immuno-gene therapy for malignant pleural mesothelioma. Cureus. 2019, 11:e4102. 10.7759\/cureus.4102","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2020.12.006","article-title":"Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab","volume":"27","author":"Mampuya WA","year":"2021","unstructured":"Mampuya WA, Bouchaab H, Schaefer N, et al.. Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab. Clin Transl Radiat Oncol. 2021, 27:85-8. 10.1016\/j.ctro.2020.12.006","journal-title":"Clin Transl Radiat Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13122","article-title":"Radiation-induced tumor immunity in patients with non-small cell lung cancer","volume":"10","author":"Lockney NA","year":"2019","unstructured":"Lockney NA, Zhang M, Morris CG, et al.. Radiation-induced tumor immunity in patients with non-small cell lung cancer. Thorac Cancer. 2019, 10:1605-11. 10.1111\/1759-7714.13122","journal-title":"Thorac Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box C","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, et al.. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017, 8:15618. 10.1038\/ncomms15618","journal-title":"Nat Commun"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"15","author":"Chung HC","year":"2020","unstructured":"Chung HC, Piha-Paul SA, Lopez-Martin J, et al.. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020, 15:618-27. 10.1016\/j.jtho.2019.12.109","journal-title":"J Thorac Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat S","year":"2020","unstructured":"Popat S, Curioni-Fontecedro A, Dafni U, et al.. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020, 31:1734-45. 10.1016\/j.annonc.2020.09.009","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel A","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L, et al.. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019, 20:239-253. 10.1016\/S1470-2045(18)30765-4","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.323","article-title":"PS01.11 nivolumab versus placebo in relapsed malignant mesothelioma: the CONFIRM phase 3 Trial","volume":"16","author":"Fennell D","year":"2021","unstructured":"Fennell D, Ottensmeier C, Califano R, et al.. PS01.11 nivolumab versus placebo in relapsed malignant mesothelioma: the CONFIRM phase 3 Trial. J Thorac Oncol. 2021, 16:62. 10.1016\/j.jtho.2021.01.323","journal-title":"J Thorac Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan R","year":"2019","unstructured":"Hassan R, Thomas A, Nemunaitis JJ, et al.. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019, 5:351-7. 10.1001\/jamaoncol.2018.5428","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio M","year":"2017","unstructured":"Maio M, Scherpereel A, Calabr\u00f2 L, et al.. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017, 18:1261-1273. 10.1016\/S1470-2045(17)30446-1","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000461","article-title":"Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma","volume":"8","author":"Hotta K","year":"2020","unstructured":"Hotta K, Fujimoto N. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma. J Immunother Cancer. 2020, 8:10.1136\/jitc-2019-000461","journal-title":"J Immunother Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.thorsurg.2020.08.001","article-title":"Mesothelioma biomarkers: discovery in search of validation","volume":"30","author":"Pass HI","year":"2020","unstructured":"Pass HI, Alimi M, Carbone M, Yang H, Goparaju CM. Mesothelioma biomarkers: discovery in search of validation. Thorac Surg Clin. 2020, 30:395-423. 10.1016\/j.thorsurg.2020.08.001","journal-title":"Thorac Surg Clin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/84354-radiation-induced-abscopal-effect-in-a-patient-with-malignant-pleural-mesothelioma-on-pembrolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:31Z","timestamp":1707507451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/84354-radiation-induced-abscopal-effect-in-a-patient-with-malignant-pleural-mesothelioma-on-pembrolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.22159","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,12]]}}}